
Custom Health Holdings Inc (TSX:CHLT) just landed Buy-rated coverage from Stifel, with analysts setting a C$12 price target and pointing to upside as high as C$18 a share. The pitch: a pill-dispensing platform that's quietly solving one of healthcare's most expensive headaches.










